enGene Holdings Inc. (NASDAQ:ENGN) Receives $29.78 Consensus Target Price from Analysts

Shares of enGene Holdings Inc. (NASDAQ:ENGN) have received a consensus recommendation of “Buy” from the eleven brokerages that are presently covering the company, MarketBeat Ratings reports. Ten research analysts have rated the stock with a buy recommendation and one has issued a strong buy recommendation on the company. The average 12-month price objective among brokers that have issued ratings on the stock in the last year is $29.78.

A number of research firms recently issued reports on ENGN. JMP Securities reissued a “market outperform” rating and issued a $18.00 price target on shares of enGene in a research note on Monday, December 23rd. Citizens Jmp raised shares of enGene to a “strong-buy” rating in a research note on Monday, November 18th. HC Wainwright began coverage on shares of enGene in a research note on Monday, December 23rd. They issued a “buy” rating and a $25.00 price target on the stock. Morgan Stanley reiterated an “overweight” rating and set a $40.00 price objective on shares of enGene in a research note on Wednesday, September 11th. Finally, Oppenheimer reissued an “outperform” rating and set a $30.00 target price on shares of enGene in a report on Tuesday, September 24th.

enGene Price Performance

NASDAQ:ENGN opened at $7.98 on Tuesday. The company has a quick ratio of 19.52, a current ratio of 19.52 and a debt-to-equity ratio of 0.09. enGene has a 52 week low of $4.42 and a 52 week high of $18.40. The stock’s 50-day moving average price is $7.67 and its 200-day moving average price is $7.66. The stock has a market capitalization of $352.84 million, a PE ratio of -13.76 and a beta of -0.78.

enGene (NASDAQ:ENGN) last issued its quarterly earnings data on Thursday, December 19th. The company reported ($0.34) EPS for the quarter, beating the consensus estimate of ($0.40) by $0.06. As a group, equities analysts expect that enGene will post -1.52 EPS for the current fiscal year.

Insider Buying and Selling at enGene

In other news, major shareholder Growth Opportunities F. Forbion bought 11,844 shares of the firm’s stock in a transaction on Monday, October 7th. The shares were bought at an average cost of $6.55 per share, for a total transaction of $77,578.20. Following the acquisition, the insider now directly owns 2,469,833 shares of the company’s stock, valued at $16,177,406.15. This trade represents a 0.48 % increase in their position. The acquisition was disclosed in a document filed with the SEC, which is available at the SEC website. 13.70% of the stock is owned by company insiders.

Institutional Trading of enGene

Several institutional investors have recently made changes to their positions in ENGN. SR One Capital Management LP acquired a new stake in enGene during the second quarter worth $4,715,000. Franklin Resources Inc. increased its position in shares of enGene by 48.7% during the 3rd quarter. Franklin Resources Inc. now owns 1,189,952 shares of the company’s stock worth $7,854,000 after purchasing an additional 389,918 shares during the last quarter. Point72 Asset Management L.P. raised its holdings in enGene by 1,410.3% in the 3rd quarter. Point72 Asset Management L.P. now owns 663,000 shares of the company’s stock valued at $4,376,000 after buying an additional 619,100 shares during the period. Logos Global Management LP lifted its position in enGene by 50.0% in the second quarter. Logos Global Management LP now owns 1,200,000 shares of the company’s stock valued at $11,316,000 after buying an additional 400,000 shares during the last quarter. Finally, Wolverine Asset Management LLC purchased a new position in enGene during the third quarter worth about $37,000. Hedge funds and other institutional investors own 64.16% of the company’s stock.

About enGene

enGene Holdings Inc, through its subsidiary enGene, Inc, operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin.